DERMATA THERAPEUTICS INC (DRMA) Stock Analyst Ratings
USA - NASDAQ:DRMA - US2498455045 - Common Stock
3.15 USD
-0.27 (-7.89%)
ChartMill assigns a Buy % Consensus number of 83% to DRMA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.2. This target is 223.81% above the current price.
DRMA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DRMA.
In the previous month the buy percentage consensus was at a similar level.
DRMA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-21 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-21 | Maxim Group | Maintains | Buy -> Buy |
| 2024-08-21 | Maxim Group | Maintains | Buy -> Buy |
| 2023-03-23 | Maxim Group | Maintains | Buy |
| 2021-09-21 | Brookline Capital | Initiate | Buy |
| 2021-09-14 | Maxim Group | Initiate | Buy |
DERMATA THERAPEUTICS INC / DRMA FAQ
What is the price target for DRMA stock?
7 analysts have analysed DRMA and the average price target is 10.2 USD. This implies a price increase of 223.81% is expected in the next year compared to the current price of 3.15.
What is the consensus rating for DERMATA THERAPEUTICS INC (DRMA) stock?
The consensus rating for DERMATA THERAPEUTICS INC (DRMA) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover DERMATA THERAPEUTICS INC (DRMA) stock?
The number of analysts covering DERMATA THERAPEUTICS INC (DRMA) is 7.